mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for FBXO5
Gene summary
Basic gene Info.Gene symbolFBXO5
Gene nameF-box protein 5
CytomapUCSC genome browser: 6q25.2
Type of geneprotein-coding
DescriptionF-box only protein 5F-box protein Fbx5early mitotic inhibitor 1
Modification date20141207
dbXrefs MIM : 606013
Ensembl : ENSG00000112029
HPRD : 09348
Vega : OTTHUMG00000015854
ProteinUniProt: Q9UKT4
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_FBXO5
BioGPS: 26271
PathwayNCI Pathway Interaction Database: FBXO5
Pathway Commons: FBXO5
ContextiHOP: FBXO5
ligand binding site mutation search in PubMed: FBXO5
UCL Cancer Institute: FBXO5
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0051436negative regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle11988738
GO:0060565inhibition of mitotic anaphase-promoting complex activity15148369

Ligand binding site mutations for FBXO5

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for FBXO5
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for FBXO5 from PDB
PDB IDPDB titlePDB structure
2M6N3D solution structure of EMI1 (Early Mitotic Inhibitor 1)

Differential gene expression and gene-gene network for FBXO5
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of FBXO5 and the right PPI network was created from samples without mutations in the LBS of FBXO5. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for FBXO5
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for FBXO5
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of FBXO5 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of FBXO5
Multiple alignments for Q9UKT4 in multiple species
LBSAA sequence# speciesSpecies
C378ESLKACIRCNS1Homo sapiens
C378ESLRRCSRCSS1Danio rerio
C378QCLKVCVDCSS1Xenopus tropicalis
C378ESLKACVRCNF1Mus musculus
C381KACIRCNSPAK1Homo sapiens
C381RRCSRCSSPAR1Danio rerio
C381KVCVDCSSPAK1Xenopus tropicalis
C381KACVRCNFPAK1Mus musculus
C396LQRATCKREGC1Homo sapiens
C396MQRAVCTRISC1Danio rerio
C396LHRATCTRESC1Xenopus tropicalis
C396LERAVCKRESC1Mus musculus
C401CKREGCGFDYC1Homo sapiens
C401CTRISCAFEFC1Danio rerio
C401CTRESCKFDFC1Xenopus tropicalis
C401CKRESCQFEYC1Mus musculus
C406CGFDYCTKCLC1Homo sapiens
C406CAFEFCTLCQS1Danio rerio
C406CKFDFCTLCSC1Xenopus tropicalis
C406CQFEYCTKCLC1Mus musculus
C409DYCTKCLCNYH1Homo sapiens
C409EFCTLCQSAFH1Danio rerio
C409DFCTLCSCKYH1Xenopus tropicalis
C409EYCTKCLCAYH1Mus musculus
C419HTTKDCSDGKL1Homo sapiens
C419HDSTPCRNTVR1Danio rerio
C419HGSKCCQTSKP1Xenopus tropicalis
C419HNNKDCLNGKI1Mus musculus
C6-----------2Danio rerio, Xenopus tropicalis
C6MSRRPCSCALR1Homo sapiens
C6MSRRTCSDLRR1Mus musculus
H414CLCNYHTTKDC1Homo sapiens
H414CQSAFHDSTPC1Danio rerio
H414CSCKYHGSKCC1Xenopus tropicalis
H414CLCAYHNNKDC1Mus musculus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas